Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination
| Autor: | Angela Fuery, Jacinta Francis, Deborah Lehmann, Mildred Lai, Anita H. J. van den Biggelaar, Christine Opa, Peter Richmond, Denise Anderson, G Saleu, William Pomat, Michael P. Alpers |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Serotype Pediatrics Physiology Antibody Response lcsh:Medicine medicine.disease_cause Biochemistry Pneumococcal conjugate vaccine Pneumococcal Vaccines Families 0302 clinical medicine Immune Physiology Cellular types Medicine and Health Sciences Medicine Public and Occupational Health 030212 general & internal medicine lcsh:Science Immune Response Children B-Lymphocytes Vaccines Immune System Proteins Multidisciplinary Vaccination Immune cells Antibody titer Antibodies Bacterial Vaccination and Immunization 3. Good health Streptococcus pneumoniae Infectious Diseases Child Preschool White blood cells Female Infants Research Article medicine.drug Cell biology Blood cells medicine.medical_specialty Infectious Disease Control Immunology 030231 tropical medicine Antibody-producing cells Antibodies Papua New Guinea 03 medical and health sciences Immunity Humans B cells Vaccines Conjugate business.industry lcsh:R Infant Newborn Infant Biology and Life Sciences Proteins Dose-Response Relationship Radiation Memory B cells Pneumococcal polysaccharide vaccine Animal cells Immunization Age Groups 13. Climate action People and Places Population Groupings lcsh:Q Preventive Medicine business |
| Zdroj: | PLoS ONE, Vol 12, Iss 10, p e0185877 (2017) PLoS ONE |
| ISSN: | 1932-6203 |
| DOI: | 10.1371/journal.pone.0185877 |
| Popis: | Trial design In an earlier trial, Papua New Guinean (PNG) children at high risk of pneumococcal disease were randomized to receive 0 or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7), followed by a single dose of 23-valent pneumococcal polysaccharide vaccine (PPV23) at 9 months of age. We here studied in a non-randomized follow-up trial the persistence of pneumococcal immunity in these children at 3–5 years of age (n = 132), and in 121 community controls of a similar age with no prior pneumococcal vaccination. Methods Circulating IgG antibody titers to all PCV7 and PPV23-only serotypes 2, 5 and 7F were measured before and after challenge with 1/5th of a normal PPV23 dose. Serotype-specific memory B-cells were enumerated at 10 months and 3–5 years of age for a subgroup of study children. Results Serotype-specific IgG antibody titers before and after challenge were similar for children who received PCV7/PPV23, PPV23 only, or no pneumococcal vaccines. Before challenge, at least 89% and 59% of children in all groups had serotype-specific titers ≥ 0.35μg/ml and ≥ 1.0 μg/ml, respectively. Post-challenge antibody titers were higher or similar to pre-challenge titers for most children independent of pneumococcal vaccination history. The rise in antibody titers was significantly lower when pre-challenge titers were higher. Overall the relative number of serotype-specific memory B-cells remained the same or increased between 10 months and 3–5 years of age, and there were no differences in serotype-specific memory B-cell numbers at 3–5 years of age between the three groups. Conclusions Immunity induced by PCV7 and/or PPV23 immunization in infancy does not exceed that of naturally acquired immunity in 3-5-year-old children living in a highly endemic area. Also, there was no evidence that PPV23 immunization in the first year of life following PCV7 priming induces longer-term hypo-responsiveness. Trial registration Clinicaltrials.gov NCT01414504 and NCT00219401. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|